HomeNewsBusinessAnnouncementsNatco receives final approval for generic Azacitidine for injection for USA market
Trending Topics
Sensex Live
Bharat Coking Coal IPO
Union Budget 2026
Amagi Media Labs IPO
Gold Rate Today

Natco receives final approval for generic Azacitidine for injection for USA market

Natco Pharma is pleased to announce final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.

June 27, 2017 / 09:28 IST
Story continues below Advertisement
Remove Ad

RECEIVES FINAL APPROVAL
FOR GENERIC AZACITIDINE FOR INJECTION (VIDAZA®) for USA market
Source : BSE

first published: Jun 27, 2017 09:28 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin youtube
Trending Topics
Sensex Today Titan Share Price Budget Date Budget 2026 Expectations Gold Price Maharashtra civic polls FIRE Rules Mahua Moitra Donald Trump Ankita Bhandari case
News
Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups
Markets
Home Currencies Commodities Pre-Market IPO Global Market Bonds
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker New Fixed Deposits Fixed Deposit Comparison Fixed Income
Mutual Funds
Home MC 30 Top Ranked Funds ETFs Mutual Fund Screener
Tools
Income Tax Calculator EMI Calculator Retirement Planning Gratuity Calculator Petrol Price in India Diesel Price in India IFSC Code
Community
Stock Markets
Network 18 Sites
News18 Firstpost CNBC TV18 News18 Hindi Cricketnext Overdrive
Quick Links
About Us Contact Us Advisory Alert Advertise with Us Disclaimer Privacy Policy Cookie Policy Terms & Conditions Financial Terms (Glossary) Sitemap Investors
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.